Research Article Details
| Article ID: | A12140 |
| PMID: | 30585337 |
| Source: | J Clin Pharm Ther |
| Title: | The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. |
| Abstract: | WHAT IS KNOWN AND OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. Some animal studies suggest that alpha-lipoic acid (ALA) can improve disease outcome. The aim of this study was to investigate the effects of ALA supplementation on liver enzymes and inflammatory markers in obese patients with NAFLD. METHODS: In the current randomized, double-blind, placebo-controlled clinical trial, 50 obese patients with NAFLD were randomly allocated to either "ALA"(received 1200 mg ALA as two capsules per day plus 400 mg vitamin E) or "placebo"(received placebo containing starch, as two capsules per day plus 400 mg vitamin E) groups for 12 weeks. Body composition and anthropometric measures, serum levels of liver enzymes, adiponectin, interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and ferritin were measured at baseline and the end of the study. RESULTS AND DISCUSSION: A total number of 45 patients completed the study (ALA group = 23; placebo group = 22). The serum concentration of IL-6 decreased significantly in ALA group in comparison with the placebo group, at end of the study (P = 0.049). Furthermore, ALA intake resulted in a significant increase in serum adiponectin levels compared to placebo (P = 0.008). A significant improvement was observed in liver steatosis grade of the patients in both groups, compared to baseline (P < 0.05). However, there was no difference between the two groups for the changes in liver steatosis, by the end of the study. Body composition and anthropometric measures, liver enzymes, MCP-1 and ferritin serum levels were not significantly different between the study groups, neither at the baseline nor at the end of the study. WHAT IS NEW AND CONCLUSION: Collectively, ALA supplementation improved serum adiponectin and IL-6 levels, without changing serum liver enzymes and liver steatosis in obese patients with NAFLD. |
| DOI: | 10.1111/jcpt.12784 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D388 | Vitamin E | Supplement | DB00163 | NR1I2; ALOX5; DGKA | Anti-inflammatory | Under clinical trials | Details |
| D007 | Alpha-lipoic acid | Chemical drug | DB00166 | LIPT1 | Antioxidant drug | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D367 | Thioctic acid | Chemical drug | DB00166 | -- | Vitamin source drug | Under clinical trials | Details |
| D463 | Alphalipoic acid | Chemical drug | DB00166 | -- | -- | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |